

POSTDOC POSITION | BRAIN METASTASIS

A postdoctoral position is available at the [Brain Metastasis Group](#) to work in an international consortia to understand brain metastasis local immunosuppression.

We are looking for a highly motivated candidate with a competitive track record in single cell approaches to develop cutting-edge research focused on the **immunosuppressive brain microenvironment**.

We look for candidates with strong expertise in **scRNAseq** (designing and performing experiments) **both on mouse and human samples**. Experience on bioinformatic analysis will be a plus. No previous experience on metastasis is required, indeed **experts on scRNAseq are welcome to apply** even though they are coming from completely different fields.

The research project is funded through ERA-NET TRANSCAN ([RISEBrain](#)). Our international consortium integrated by six members in Germany, Italy, Israel and Turkey aims to dissect and functionally validate key components of brain immunosuppression relevant for metastatic disease when affecting this organ. We have access to state-of-the-art pre-clinical resources and patient derived materials ([RENACER](#)) as well as the adequate environment to develop a very ambitious and competitive project with the final goal of generating novel immunotherapeutic strategies.

Besides the exciting project we offer a great lab environment and a well-funded research program in a top research institution within the vibrant city of Madrid (Spain). The laboratory will support initiatives to promote the scientific career of postdoctoral trainees. In this sense, although the position is funded, candidates will be encouraged to obtain their own postdoctoral fellowships.

To be considered for this position candidates must submit a single pdf document to mvaliente@cnio.es containing: cover letter (1 page), CV (2 pages max) and 3 references (no letters are needed at this point). Those candidates not following this application format will not be considered.

Recent lab publications:

[Monteiro, Miarka et al. Nature Medicine \(2022\)](#)

[Zhu et al. EMBO Molecular Medicine \(2022\)](#)

[Priego et al. Nature Medicine \(2018\)](#)

CNIO is one of the top institutions for cancer research in Europe, with access to a broad variety of core facilities and an excellent scientific environment. Its international working environment promotes equal opportunities for men and women, regardless of their nationality, age, race, religion and beliefs, disability and sexual orientation, under criteria of scientific excellence.